Oral cannabis did not affect dyskinesia in Parkinson's disease
Oral cannabis did not affect dyskinesia in Parkinson's disease
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study
Neurology. 2004 Oct 12;63(7):1245-50.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
19 patients with Parkinson's disease and levodopa-induced dyskinesia completed a 4-week oral cannabis dose-escalation study followed by a randomized crossover trial of cannabis versus placebo (4 weeks each phase). The primary outcome was the Unified Parkinson's Disease Rating Scale dyskinesia score. There was no evidence of any effects on Parkinson's or dyskinesia symptoms. Cannabis was well-toler...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.